Interferon Alfa 2b
Links shared publicly online about this topic
Adjuvant chemoradiation plus interferon alfa-2b did not improve survival in pancreatic cancer | HemOncToday
hemonctoday.com — “Adjuvant chemoradiation plus interferon alfa-2b did not improve survival in pancreatic cancer | HemOncToday” View full resource at hemonctoday.com
Most Recently Shared on June 23, 2010 at 6:25 pm By:
HemOnc Today Oncology and Health News
Adjuvant chemoradiation plus interferon alfa-2b did not improve survival in pancreatic cancer http://ht.ly/22dEz
EADO: No difference between pegylated, conventional interferon alfa-2b for melanoma | HemOncToday
hemonctoday.com — “EADO: No difference between pegylated, conventional interferon alfa-2b for melanoma | HemOncToday” View full resource at hemonctoday.com
Most Recently Shared on June 5, 2010 at 10:15 pm By:
HemOnc Today Oncology and Health News
EADO: No difference between pegylated, conventional interferon alfa-2b for melanoma http://ht.ly/1UzGp #ASCO10
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial : The Lancet Oncology
thelancet.com — “Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. By - Dr Johan Hansson MD, P...” View full resource at thelancet.com
Most Recently Shared on January 31, 2011 at 2:36 am By:
[Articles] Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients wit... http://bit.ly/iiQbTv
interferon alfa effective in behcet's
eyedocnews.com — “dose-escalating interferon controlled behcet's in 95% of patients” View full resource at eyedocnews.com
Most Recently Shared on April 12, 2011 at 9:32 am By:
Dr. Ari Weitzner Doctor, Ophthalmologist, and Physician
Discuss: Interferon Controls Behcet’s Disease: Archives: Behcet’s disease is an uncommon inflammatory disease wh... http://bit.ly/fXk5i4
FDA Approves Peginterferon Alfa-2b for Melanoma - Skin & Allergy News
skinandallergynews.com — “Skin & Allergy News Digital Network is the online destination and multimedia properties of Skin & Allergy News, the independent news publication for the dermatology community. Our breaking news covers all areas of medical dermatology, dermatologic surgery, and aesthetic dermatology. We also provide the news by specialty interest: acne and rosacea, atopic dermatitis and eczema, cutaneous oncology, hair and nails, infectious diseases, pediatric dermatology, psoriasis and rheumatologic disorders, s” View full resource at skinandallergynews.com
Most Recently Shared on April 19, 2011 at 9:28 pm By:
Lisa Kates, M.D. Dermatologist, Physician, and Doctor
FDA Approves Peginterferon Alfa-2b for Melanoma - Skin & Allergy News http://t.co/tLWqK4B via @AddThis
FDA Approves Peginterferon Alfa-2b for Melanoma : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on April 13, 2011 at 9:44 pm By:
Bob Finn - Medical News Net Health News
For node+ melanoma, FDA approves peginterferon alfa-2b, 1st adjuvant therapy approved in >15 yrs. @aliciaault reports. http://bit.ly/fzGy1r
Pharmasset Initiates Phase 2b Clinical Trial Of PSI-7977 For Chronic Hepatitis C Genotypes 1, 2, And 3
medicalnewstoday.com — “Pharmasset, Inc. (Nasdaq: VRUS) announced that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial” View full resource at medicalnewstoday.com
Most Recently Shared on August 25, 2010 at 3:00 pm By:
Pharmasset Initiates Phase 2b Clinical Trial Of PSI-7977 For Chronic Hepatitis C Genotypes 1, 2, And 3 http://mnt.to/3HPd #liver #hepatitis
FDA Approves Peginterferon Alfa-2b (Sylatron(tm)), For Adjuvant Melanoma
medicalnewstoday.com — “In collaboration with the Food and Drug Administration (FDA), and as a service to our members, ASCO will provide updates on recent FDA approvals and other important FDA actions (e.g., updated safe” View full resource at medicalnewstoday.com
Most Recently Shared on April 1, 2011 at 9:05 am By:
FDA Approves Peginterferon Alfa-2b (Sylatron(tm)), For Adjuvant Melanoma http://mnt.to/3T34 #skincancer #melanoma
FDA Approves Merck's Sylatron (peginterferon alfa-2b) for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement
drugs.com — “Sylatron (peginterferon alfa-2b) is used for the adjuvant treatment of melanoma. Includes Sylatron side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on April 13, 2011 at 11:43 pm By:
FDA Approves Merck's Sylatron (peginterferon alfa-2b) for the Adjuvant Treatment of Melanoma - http://bit.ly/f4t9Dr
FDA Approves Merck's Sylatron (peginterferon alfa-2b) for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement
drugs.com — “Sylatron (peginterferon alfa-2b) is used for the adjuvant treatment of melanoma. Includes Sylatron side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on April 14, 2011 at 12:11 am By:
Drugs and Devices OW OW Health
FDA Approves Merck's Sylatron (peginterferon alfa-2b) for Injection, a New Adjuvant Treatment for Melanoma... http://bit.ly/fpTNTP #drug
ZymoGenetics Initiates PEG-Interferon Lambda Phase 2b Clinical Trial In Hepatitis C In Collaboration With Bristol-Myers Squibb
medicalnewstoday.com — “ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-nave patients with ch” View full resource at medicalnewstoday.com
Most Recently Shared on June 4, 2010 at 11:06 am By:
ZymoGenetics Initiates PEG-Interferon Lambda Phase 2b Clinical Trial In Hepatitis C In Collaboration With Bristol-Myer... http://mnt.to/3Dvs
Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful
news-medical.net — “Helix BioPharma Corp. today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug ("pre-IND") meetings with the U.S. Food and Drug Administration ("FDA").” View full resource at news-medical.net
Most Recently Shared on October 8, 2009 at 1:01 am By:
Lung Cancer News: Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha.. http://digg.com/u1DrN8
Helix BioPharma Corp. Completes Enrollment In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts
medicalnewstoday.com — “Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) announced that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollmen” View full resource at medicalnewstoday.com
Most Recently Shared on November 6, 2009 at 3:21 pm By:
MNT Clinical Trials Health News
Helix BioPharma Corp. Completes Enrollment In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients Wit.. http://bit.ly/IbiLS
Oncology Medical News about Carcinoma, Renal Cell Interferon Alfa-2a
mdlinx.com — “Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma : An open-label randomised trial” View full resource at mdlinx.com
Most Recently Shared on February 22, 2010 at 9:43 am By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Oncology Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in... http://bit.ly/bj93W1
Oncology Medical News about Carcinoma, Renal Cell Interferon Alfa-2a
mdlinx.com — “Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): An open-label randomised trial” View full resource at mdlinx.com
Most Recently Shared on February 12, 2010 at 9:33 am By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Oncology Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in... http://bit.ly/clZRAX
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
HemOnc Today
The official Twitter feed for HemOnc Today, offering news and perspectives in hematology and oncology.
-
HemOnc Today
The official Twitter feed for HemOnc Today, offering news and perspectives in hematology and oncology.
-
Skin Cancer OW
Organizing skin cancer resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
